TDF induced IFN-λ3 secretion in WiDr and HT-29 colon cancer cells after 48 hours, with a dose-dependent response. The tested non-colon cell panel did not show induction by the nucleos(t)ide analogues despite responsiveness to positive controls. This response is cell-type-dependent. [2]
In serum-starved HepG2 cells, 50 μM TDF pretreatment for 24 hours reduced insulin-stimulated INSRβ phosphorylation and downstream signaling relative to untreated and entecavir-treated conditions. These host-cell observations do not establish clinical cancer prevention or a receptor inhibition constant. [3]
Cellular formation of tenofovir diphosphate from TDF
Cell-based study · Human vaginal epithelial VK2 cells [1]
TDF exposure generated mono-protected TFV, TFV, TFV-MP and TFV-DP. Intracellular TFV and phosphorylated products were similar at 90 and 450 μM TDF; metabolite formation was nonlinear.
Literature-Reported Treatment Conditions
- Treatment concentration
- TDF: 90 and 450 μM; separate TFV comparator: 450 and 1,350 μM
- Exposure duration
- 15 min to 12 h
- Method
- HPLC-MS/MS of cell-associated parent drug and metabolites; serum-free RPMI 1640 at 37°C
- Co-treatment
- None; TFV was a separate comparator
- Reported limits
- Vehicle is not specified in Figure 6/caption. At 90 μM TDF only one assay was performed.
Methods and source locations
Compound reported in the paper: Tenofovir disoproxil fumarate; Compound label in the paper: TDF
Cellular prodrug activation; no direct antiviral efficacy or human exposure extrapolation.
Reagents; kinetics methods; Results: Kinetics of TDF and TFV uptake and metabolism; Figure 6 image/caption
Formation of TFV-MP and TFV-DP after TDF exposure: HPLC-MS/MS; duplicate measurements of a representative of two independent assays at 450 μM TDF; one assay at 90 μM — Figure 6A–D and Results: Kinetics of TDF and TFV uptake and metabolism
Esterase inhibition lowers cell-associated TDF-derived radioactivity
Cell-based study · VK2 cells and human PBMCs [1]
BNPP reduced cell-associated radiolabeled TDF without significantly reducing radiolabeled TFV accumulation; MTS supported absence of overt BNPP cytotoxicity under the tested conditions.
Literature-Reported Treatment Conditions
- Treatment concentration
- 0.5 μM [3H]TDF or [3H]TFV; 100 μM BNPP pretreatment
- Exposure duration
- BNPP pretreatment 1 h; drug exposure 1 h; viability after 2 h BNPP
- Method
- Liquid scintillation counting of washed cells; MTS viability assay
- Co-treatment
- BNPP plus labeled drug compared with no BNPP; TFV comparator tested separately
- Reported limits
- Vehicle not specified in selected transport subsection/caption. Cell-associated radioactivity includes parent and metabolites.
Methods and source locations
Compound reported in the paper: Tenofovir disoproxil fumarate; Compound label in the paper: TDF
Supports an esterase contribution to cellular retention; does not identify a unique causal CES isoform.
Reagents; Drug transport assays; Results: Esterase inhibition reduces TDF accumulation; Figure 5 image/caption
Reduction in TDF-associated cellular radioactivity in VK2: Means ± SEM; two independent experiments performed in duplicate; unpaired Student t test, figure *** P < 0.001 — Esterase inhibition Results; Figure 5
Reduction in TDF-associated cellular radioactivity in PBMCs: Means ± SEM; two independent experiments performed in duplicate; unpaired Student t test, figure *** P < 0.001 — Esterase inhibition Results; Figure 5
TFV accumulation and BNPP viability controls: TFV tracer and MTS controls — Esterase inhibition Results; Figure 5
Cell-type-specific IFN-λ3 induction
Cell-based study · WiDr and HT-29 colon cancer cells; negative panel spanning PBMCs, PXB hepatocytes and several non-colon cell lines [2]
TDF induced secreted IFN-λ3 in the two colon cancer cell lines, with a dose-dependent response. NUCs did not induce IFN-λ3 in the Figure 3 non-colon panel despite positive-control responsiveness.
Literature-Reported Treatment Conditions
- Treatment concentration
- TDF 50 μM and serial 1:3 dilutions; comparator LAM 50 μM, ADV 2.5 μM, ETV 0.25 μM
- Exposure duration
- 48 h
- Method
- In-house chemiluminescence enzyme immunoassay of supernatants
- Vehicle
- 0.1% DMSO negative control
- Co-treatment
- None for selected TDF arm. IFN-α with or without poly I:C or R-837 served as positive controls, not TDF combinations.
- Reported limits
- Numerical dose-response parameters are not tabulated; no curve digitization. Supplementary assay details were not retrieved.
Methods and source locations
Compound reported in the paper: Tenofovir disoproxil fumarate; Compound label in the paper: TDF
Host-cell IFN-λ3 response in these models only. Downstream conditioned-medium effects used ADV and are not attributed to TDF.
Cell culture; Measurement of IFNs; Results: negative cell panel and colon-cell induction; Figures 3 and 4A–B images/captions
Secreted IFN-λ3 in WiDr and HT-29: Chemiluminescence enzyme immunoassay; Figure 4 caption reports at least three independent experiments in triplicate, representative data shown — Figure 4A–B and caption; colon cancer cell Results
IFN-λ3 in non-colon cell panel: Same 48 h assay with DMSO and positive controls — Figure 3 image/caption and preceding Results
Suppression of insulin-stimulated signaling in HepG2 cells
Cell-based study · Serum-starved HepG2 hepatoma cells [3]
TDF pretreatment reduced insulin-stimulated INSRβ phosphorylation and downstream IRS1/AKT and Gab1/SHP2 signaling relative to untreated and entecavir-treated cells.
Literature-Reported Treatment Conditions
- Treatment concentration
- 50 μM TDF; ETV and ADV comparator pretreatments also 50 μM; insulin 100 μM as reported
- Exposure duration
- Serum starvation 24 h; drug pretreatment 24 h; insulin 30 or 180 min
- Method
- Western blotting of phosphorylated and total pathway proteins
- Co-treatment
- Insulin stimulation after TDF pretreatment; untreated and ETV controls
- Reported limits
- Vehicle, biological replicate count and inferential statistics for Figure 4 blots are not specified in the selected caption.
Methods and source locations
Compound reported in the paper: Tenofovir disoproxil fumarate; Compound label in the paper: TDF
Additional host-cell signaling observation, not proof of clinical cancer prevention or an INSR enzyme IC50.
Cell culture and reagents; Western blotting; Results: Effects of NtAs on INSR signaling; Figure 4A,C,D images/caption
Insulin-stimulated receptor and downstream phosphorylation: Western blotting with total-protein and β-actin controls; no curve-derived fold change — Figure 4C–D and INSR signaling Results